Skip to main content

CORRECTION article

Front. Neurol., 01 December 2022
Sec. Endovascular and Interventional Neurology
Volume 13 - 2022 | https://doi.org/10.3389/fneur.2022.1055700

Corrigendum: Clinical value and prognosis of C reactive protein to lymphocyte ratio in severe aneurysmal subarachnoid hemorrhage

This article is a correction to:

  1. Clinical Value and Prognosis of C Reactive Protein to Lymphocyte Ratio in Severe Aneurysmal Subarachnoid Hemorrhage

    1. Read original article
\nQingqing Zhang,&#x;Qingqing Zhang1,2†Gaoqi Zhang,&#x;Gaoqi Zhang1,2†Lintao WangLintao Wang2Wanwan Zhang,Wanwan Zhang1,2Fandi HouFandi Hou1Zhanqiang ZhengZhanqiang Zheng1Yong GuoYong Guo1Zhongcan Chen,Zhongcan Chen1,3Juha HernesniemiJuha Hernesniemi3Hugo Andrade-BarazarteHugo Andrade-Barazarte3Guang Feng, Guang Feng1,3*Jianjun Gu, Jianjun Gu1,2*
  • 1Department of Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China
  • 2School of Clinical Medicine, Henan University, Kaifeng, China
  • 3Department of Neurosurgery, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China

A corrigendum on
Clinical value and prognosis of C reactive protein to lymphocyte ratio in severe aneurysmal subarachnoid hemorrhage

by Zhang, Q., Zhang, G., Wang, L., Zhang, W., Hou, F., Zheng, Z., Guo, Y., Chen, Z., Hernesniemi, J., Andrade-Barazarte, H., Feng, G., and Gu, J. (2022). Front. Neurol. 13:868764. doi: 10.3389/fneur.2022.868764

In the published article, there was an error in the article type. Instead of “Review,” it should be “Original Research”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: aneurysmal subarachnoid hemorrhage (aSAH), C-reactive protein (CRP), lymphocytes, C-reactive protein to lymphocyte ratio (CLR), prognosis, outcome

Citation: Zhang Q, Zhang G, Wang L, Zhang W, Hou F, Zheng Z, Guo Y, Chen Z, Hernesniemi J, Andrade-Barazarte H, Feng G and Gu J (2022) Corrigendum: Clinical value and prognosis of C reactive protein to lymphocyte ratio in severe aneurysmal subarachnoid hemorrhage. Front. Neurol. 13:1055700. doi: 10.3389/fneur.2022.1055700

Received: 28 September 2022; Accepted: 10 November 2022;
Published: 01 December 2022.

Edited and reviewed by: Sarah Elizabeth Nelson, Mount Sinai Health System, United States

Copyright © 2022 Zhang, Zhang, Wang, Zhang, Hou, Zheng, Guo, Chen, Hernesniemi, Andrade-Barazarte, Feng and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jianjun Gu, gujianjundt@163.com; Guang Feng, fgwxh@163.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.